Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$122.54M+6.5%-$131.12M
$2.16M-10.0%$2.4M-7.9%$2.61M-7.7%$2.83M-6.8%$3.03M-8.1%
$20.28M+23.7%$16.4M+24.4%$13.18M+13.0%$11.66M+10.4%$10.56M+9.5%
-$121.54M-8.6%-$111.94M
$588K-25.9%$794K-41.8%$1.37M-2.5%$1.4M+20.0%$1.17M+1.7%
-$164.39M+3.8%-$170.96M-151%-$68.18M-4,770%-$1.4M-20.0%-$1.17M-1.7%
$190.32M-30.9%$275.34M-19.5%$342.01M+72.5%$198.25M+0.2%$197.79M+108%
-$95.61M-1,164%-$7.57M-105%$167.17M
-$122.13M-8.3%-$112.73M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Maze Therapeutics, Inc. Common Stock generate?
Maze Therapeutics, Inc. Common Stock (MAZE) generated -$121.5M in operating cash flow over the trailing twelve months.
What is Maze Therapeutics, Inc. Common Stock's free cash flow?
After $588.0K of capital expenditures, Maze Therapeutics, Inc. Common Stock's free cash flow was -$122.1M over the trailing twelve months.
Where does Maze Therapeutics, Inc. Common Stock's cash flow data come from?
Every line is extracted from Maze Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.